Compare Halliburton Company (HAL) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halliburton Company vs Incyte Corporation — how do they compare? Halliburton Company trades at $32.56 (market cap $27.14B), while Incyte Corporation trades at $113.17 (market cap $22.85B). The key difference: Halliburton Company is the larger of the two by market cap, and Halliburton Company pays a 2.09% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halliburton Company for 89 Days and Incyte Corporation for 33 Days on average.
| HAL | INCY | |
|---|---|---|
Market Cap | $27.14B | $22.85B |
Volume | 11,258,156 | 1,927,029 |
Sector | Energy | Health |
52-Week High | $42.98 | $129.93 |
52-Week Low | $21.82 | $83.80 |
Typical Hold Time | 89 Days | 33 Days |
Enterprise Value | $33.29B | $18.35B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $32.57, up 2.58% today, with a bearish technical signal despite recent earnings beats. The company shows solid profitability with a 7.16% net income margin and 14.89% ROE, though revenue dipped slightly in 2025. Recent news highlights expansion in Venezuela and a new deepwater contract in Cyprus, signaling growth initiatives. Analyst consensus is strongly bullish with a $43.11 price target, but technical indicators and recent CFO stock sales introduce caution.
The outlook for HAL is mixed; strong analyst support and strategic contracts offer upside, but technical weakness and exposure to oil price volatility pose risks. Investors should weigh the company's solid fundamentals and growth projects against market sentiment and industry cyclicality for balanced decision-making.
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
